Retatrutide
A next-generation triple agonist peptide currently being researched for metabolic health, appetite regulation and weight management.
- 5mg
- 10mg
- 15mg
- 20mg
- 30mg
- 40mg
- 60mg
All formats × 10 vials. Supplied strictly for laboratory research purposes only.
Research use only Research use only. Not a medicine, not a supplement, not approved for human or animal use. No medical advice or dosage guidance provided.
Illustrative packaging. Actual presentation may vary.
Overview
Retatrutide is a next generation triple agonist peptide currently being researched for weight management, metabolic health and appetite regulation. Unlike traditional GLP-1 compounds, Retatrutide targets three separate hormone receptors including GLP-1, GIP and glucagon receptors.
Research areas
Research investigates the following endpoints:
- Fat mass and body composition in research models
- Appetite and food-intake measures in research models
- Insulin sensitivity measures
- Energy expenditure and metabolic activity
- Glucose regulation research
- Long-term body composition research
These research areas describe study endpoints, not established benefits of the materials supplied here.
How it works
Retatrutide (LY3437943) is a next-generation triple agonist peptide that simultaneously activates GLP-1, GIP and glucagon receptors. It is one of the most advanced metabolic research peptides currently under investigation, studied for its potential to address multiple aspects of energy regulation through a single compound. Research has focused on its effects on appetite suppression, insulin sensitivity, hepatic fat metabolism and resting energy expenditure. The triple receptor engagement differentiates it from earlier single or dual agonist compounds such as Semaglutide and Tirzepatide. Available in 5mg, 10mg, 15mg, 20mg, 30mg, 40mg and 60mg vial formats.
Scientific information
Retatrutide vs Semaglutide vs Tirzepatide
| Feature | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptor targets | GLP-1 + GIP + Glucagon | GLP-1 + GIP | GLP-1 only |
| Generation | Triple agonist | Dual agonist | Single agonist |
| Research focus | Metabolic + energy expenditure | Metabolic + incretin | Incretin + appetite |
| Available sizes | 5-60mg | 2-100mg | 5-30mg |
Important information
Research use only. Not a medicine, not a supplement, not approved for human or animal use.
Cambridge Health™ does not provide usage, dosage, reconstitution or administration guidance for any product. Product information on this page is provided for research and educational context only.
Safety information
- Supplied strictly for laboratory and analytical research use. Not for human or animal consumption.
- No medical advice, treatment guidance or personal use recommendations are provided.
- Buyers are solely responsible for ensuring that the purchase, import, handling and use of research materials is lawful in their jurisdiction.
Research status
Supplied for laboratory research use only. Not a licensed medicine and not approved for human or animal use.